{"gene":"BCL2L10","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1999,"finding":"Boo (BCL2L10) interacts with Apaf-1 and forms a multimeric protein complex with Apaf-1 and caspase-9; pro-apoptotic Bak and Bik disrupt the Boo-Apaf-1 association. Boo also binds three distinct regions of Apaf-1.","method":"Co-immunoprecipitation, pulldown assays, transfection-based apoptosis assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with multiple binding partners, disruption by pro-apoptotic proteins, replicated with multiple orthogonal methods in a single rigorous study","pmids":["9878060"],"is_preprint":false},{"year":1999,"finding":"Boo (BCL2L10) localizes to intracellular membranes via its hydrophobic C-terminus and inhibits apoptosis; it homodimerizes and heterodimerizes with other Bcl-2 family members.","method":"Subcellular fractionation, co-immunoprecipitation, transfection-based apoptosis assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — localization by fractionation tied to function, dimerization by Co-IP, multiple orthogonal methods","pmids":["9878060"],"is_preprint":false},{"year":2001,"finding":"Bcl-B (BCL2L10) contains BH1, BH2, BH3, BH4, and a C-terminal transmembrane domain; it binds Bcl-2, Bcl-XL, and Bax but NOT Bak. It suppresses Bax-induced but not Bak-induced apoptosis. Deletion of the TM domain impairs association with intracellular organelles and diminishes anti-apoptotic function.","method":"Co-immunoprecipitation, GST pulldown, transient transfection apoptosis assays, domain deletion mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, functional mutagenesis (TM deletion), multiple orthogonal methods in one study","pmids":["11278245"],"is_preprint":false},{"year":2001,"finding":"Bcl2-L-10 blocks apoptosis in the mitochondrial death pathway (preventing cytochrome C release, caspase-3 activation, and mitochondrial membrane potential collapse) but does not block TNFα-induced (death receptor) apoptosis. Both the BH4 domain and transmembrane domain are necessary for its anti-apoptotic function.","method":"Transfection assays, cytochrome C release measurement, caspase-3 activation assay, mitochondrial membrane potential assay, domain deletion mutagenesis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal functional readouts, domain mutagenesis establishing necessary elements, pathway placement by comparison with death receptor pathway","pmids":["11689480"],"is_preprint":false},{"year":2003,"finding":"Bcl-B selectively binds Bax over Bak via the BH3 domain of Bax; chimeric Bak containing Bax's BH3 domain bound Bcl-B whereas chimeric Bax containing Bak's BH3 domain did not. Alanine-scanning of Bax BH3 and structure-based mutations in Bcl-B's BH3-binding pocket (L86A and R96Q) abolished Bax binding and apoptosis suppression, confirming binding-dependent suppression mechanism.","method":"BH3-swap chimeric mutant co-immunoprecipitation, alanine-scanning mutagenesis, structure-based mutagenesis of BH3-binding pocket, transient transfection apoptosis assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro mutagenesis with functional readouts, multiple orthogonal approaches establishing molecular basis of selectivity","pmids":["12921534"],"is_preprint":false},{"year":2007,"finding":"Nuclear receptor Nur77/TR3 selectively binds Bcl-B among anti-apoptotic Bcl-2 family members and converts Bcl-B from anti-apoptotic to pro-apoptotic. Endogenous Bcl-B associates with endogenous Nur77 in RPMI 8226 myeloma cells, and RNAi knockdown of Bcl-B demonstrated dependence on Bcl-B for Nur77-induced apoptosis.","method":"Co-immunoprecipitation of endogenous proteins, RNAi knockdown, fluorescence polarization binding assay, peptide treatment assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — endogenous Co-IP, RNAi epistasis, binding specificity profiled across all 6 family members, multiple orthogonal methods","pmids":["17227826"],"is_preprint":false},{"year":2007,"finding":"NM23-H2 interacts with Diva/BCL2L10 (requiring the transmembrane domain of Diva) and co-localizes in cytoplasm. NM23-H2 overexpression down-regulates Diva protein level; NM23-H2 knockdown restores Diva expression and increases Diva-mediated apoptotic activity.","method":"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, subcellular co-localization","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain requirement, siRNA functional validation, single lab with two orthogonal methods","pmids":["17532299"],"is_preprint":false},{"year":2008,"finding":"Bcl-B shows strong preference for binding and suppressing Bax over Bak, in contrast to Bcl-2, Bcl-XL, Bcl-W, and Bfl-1 which bind both. Bcl-B is not targeted by ABT-737 due to low affinity.","method":"Co-immunoprecipitation, GST pulldown, fluorescence polarization with synthetic BH3 peptides, transient transfection apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent binding methods plus functional assays, comparative profiling across all anti-apoptotic family members","pmids":["18178565"],"is_preprint":false},{"year":2009,"finding":"HIP1R interacts with BCL2L10 (requiring both ANTH and THATCH domains of HIP1R); HIP1R overexpression induces cell death dependent on BAK (not BAX), associated with mitochondrial membrane potential loss and caspase-9 activation, and augments BCL2L10-caspase-9 association.","method":"Yeast two-hybrid, co-immunoprecipitation, Far-Western analysis, domain deletion, caspase-9 activation assay, mitochondrial membrane potential assay","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirmed by Far-Western, domain mapping, functional phenotype, single lab","pmids":["19255499"],"is_preprint":false},{"year":2009,"finding":"BCL2L10 protein is associated with the microtubule binding protein TCTP (translationally controlled tumor protein) and with mitochondria in oocytes, with stage-specific redistribution along the pericortical regulatory ooplasm. Neutralization of BCL2L10 accelerated oocyte death.","method":"Co-immunoprecipitation, immunofluorescence, neutralizing antibody treatment, subcellular fractionation","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and localization imaging with functional consequence (neutralization accelerates death), single lab","pmids":["19551325"],"is_preprint":false},{"year":2009,"finding":"Bcl2l10 RNAi in mouse germinal vesicle oocytes causes metaphase I arrest with spindle and chromosome abnormalities; Bcl2l10 affects maturation-promoting factor activity but not MAPK activity at the MI-MII transition.","method":"Microinjection of dsRNA, immunofluorescence for spindle/chromosomes, MPF and MAPK activity assays","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi loss-of-function with specific cellular phenotype and pathway placement, single lab","pmids":["19439730"],"is_preprint":false},{"year":2012,"finding":"BCL2L10 (BCLb) protein stability is regulated by Ubiquilin1 (Ubqln1), which specifically interacts with BCLb (but not other anti-apoptotic BCL2 family members), stabilizes BCLb protein, promotes its monoubiquitination on multiple lysine residues, and relocalizes it to the cytosol.","method":"Immunoaffinity purification, mass spectrometry, cycloheximide chase, co-immunoprecipitation, ubiquitination assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — mass spectrometry identification confirmed by Co-IP, functional stability assay, specificity demonstrated across family members, multiple orthogonal methods","pmids":["22233804"],"is_preprint":false},{"year":2012,"finding":"Bcl-B is polyubiquitinated at steady state via K48-linked chains; K128 is the primary acceptor site (confirmed by mass spectrometry and linkage-specific antibodies), with K119 and K120 as additional sites. Ubiquitination targets Bcl-B for proteasomal degradation and controls its anti-apoptotic capacity. A lysineless Bcl-B mutant shows 5-fold higher protein expression than wild-type.","method":"Mutagenesis (lysine substitutions), mass spectrometry, linkage-specific ubiquitin antibodies, proteasome inhibition, cycloheximide chase","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-specific mutagenesis, MS confirmation of ubiquitination site, linkage-specific antibodies, multiple orthogonal methods in one study","pmids":["23563182"],"is_preprint":false},{"year":2012,"finding":"Bcl-B interacts with the BH3 domain of BECN1 (Beclin-1) and inhibits autophagy; Bcl-B overexpression reduces autophagy triggered by various stimuli while Bcl-B knockdown triggers autophagic cell death dependent on LC3, BECN1, and ATG5.","method":"Co-immunoprecipitation, autophagy flux assays, siRNA knockdown, overexpression studies","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of endogenous proteins, RNAi with specific autophagy pathway dependency, single lab with two orthogonal methods","pmids":["22498477"],"is_preprint":false},{"year":2012,"finding":"Bcl-B has high-affinity interactions with Bim and Bik BH3-only proteins only; it does not bind other BH3-only proteins with high affinity. Crystal structure of Bcl-B:Bim complex resolved to 1.9 Å reveals an insertion of an unstructured loop between helices α5 and α6 distinguishing Bcl-B from other family members.","method":"X-ray crystallography (1.9 Å resolution), fluorescence polarization binding assays, cell-based apoptosis assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with biophysical binding assays and cell-based functional validation, comprehensive BH3-only protein profiling","pmids":["23235460"],"is_preprint":false},{"year":2012,"finding":"Bcl-B is not targeted by ABT-737 (low affinity), in contrast to Bcl-2, Bcl-xL, and Bcl-w. Noxa, but not Bim, Puma, or truncated Bid, can overcome Bcl-B-mediated resistance to ABT-737.","method":"Inducible expression system, cell-based apoptosis assays with BH3-only protein expression, drug treatment experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional epistasis with inducible expression, single lab, clear mechanistic result on selectivity","pmids":["22875003"],"is_preprint":false},{"year":2016,"finding":"IRBIT interacts with Bcl2l10 and they additively inhibit IP3R in the physiological state. Upon apoptotic stress, IRBIT is dephosphorylated and becomes an inhibitor of Bcl2l10. The IRBIT-Bcl2l10 complex associates in mitochondria-associated membranes (MAMs); IRBIT promotes ER-mitochondria contact and facilitates Ca2+ transfer to mitochondria to promote apoptosis by inhibiting Bcl2l10.","method":"Co-immunoprecipitation, IP3R activity assays, phosphorylation assays, subcellular fractionation (MAM isolation), Ca2+ imaging, IRBIT knockdown","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including biochemical reconstitution in MAMs, Ca2+ functional assays, phosphorylation state dependency, mechanistic model with multiple supporting experiments","pmids":["27995898"],"is_preprint":false},{"year":2016,"finding":"Bcl2l10 co-localizes on meiotic spindles with Tpx2 and Aurora kinase A (Aurka); Bcl2l10 is present in the same complex as Tpx2. Bcl2l10 RNAi decreases Tpx2 and Aurka expression while increasing phospho-Aurka, resulting in decreased Aurka catalytic activity, disrupted MTOC formation, and impaired meiotic spindle assembly.","method":"Co-immunoprecipitation, immunofluorescence co-localization, RNAi, kinase activity assay","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and co-localization, RNAi with kinase activity readout, single lab with multiple methods","pmids":["27753540"],"is_preprint":false},{"year":2018,"finding":"Nrh/BCL2L10 localizes to the endoplasmic reticulum and makes BH4 domain-dependent interactions with the ligand-binding domain of IP3R (type 1/3 Ca2+ channel), negatively regulating ER-Ca2+ release to mediate anti-apoptosis. Disrupting Nrh/IP3R complexes with BH4 mimetic peptides inhibits breast cancer cell growth in vitro and in vivo.","method":"Immunofluorescence/confocal localization, co-immunoprecipitation, BH4-domain deletion mutagenesis, Ca2+ release assays, in vitro and in vivo tumor growth assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — domain mutagenesis, Co-IP, functional Ca2+ assays, in vivo validation, multiple orthogonal methods in one study","pmids":["29330143"],"is_preprint":false},{"year":2019,"finding":"BCL-B binds phospho-Parkin directly and inhibits its phosphorylation, thereby suppressing mitophagy in hepatic stellate cells. BCL-B knockdown increases both mitophagy and apoptosis in HSCs, while BCL-B overexpression has the opposite effects.","method":"Co-immunoprecipitation of BCL-B with phospho-Parkin, siRNA knockdown, overexpression, mitophagy assays, apoptosis assays","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with phospho-Parkin, bidirectional gain/loss-of-function with specific mitophagy phenotype, single lab","pmids":["30635551"],"is_preprint":false},{"year":2019,"finding":"BCL2L10 interacts with BECN1 (Beclin-1) in hepatoma cells; this interaction reduces the association between BECN1 and PI3KC3, thereby suppressing autophagy via the PI3K/AKT signaling pathway.","method":"Co-immunoprecipitation, ELISA, immunofluorescence co-localization, autophagic flux monitoring (LC3B-II/P62), PI3K/AKT pathway analysis","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing competitive binding between BCL2L10-BECN1 and BECN1-PI3KC3, multiple orthogonal methods, single lab","pmids":["30696802"],"is_preprint":false},{"year":2020,"finding":"BCL2L10 expression is driven by STAT3-mediated transcription; functional STAT3 responsive elements were identified in the BCL2L10 promoter. BCL2L10 confers resistance to cisplatin, dacarbazine, and ABT-737 in melanoma; genetic and pharmacological inhibition of BCL2L10 sensitized cells to cisplatin and ABT-737.","method":"Reporter assays, site-directed mutagenesis of STAT3 binding sites, ChIP analysis, siRNA knockdown, pharmacological inhibition","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter assays, and mutagenesis for transcriptional regulation; functional siRNA with drug sensitivity readouts, single lab","pmids":["33396645"],"is_preprint":false},{"year":2021,"finding":"UBQLN4 interacts with and stabilizes BCL2L10, preventing mesothelioma cell apoptosis in response to DNA damage. UBQLN4 itself is a substrate of ATM kinase.","method":"Co-immunoprecipitation, functional genetic screening, apoptosis assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP interaction with functional consequence, genetic screening context, single lab","pmids":["34245648"],"is_preprint":false},{"year":2011,"finding":"Human BCL2L10 has evolved a calcium-binding motif in its α5-α6 interhelical region through acquisition of critical negatively charged residues. Deletion of the N-terminal extension had no significant functional impact in HeLa cells, but the interhelical region mutation affects function.","method":"Site-directed mutagenesis, truncation constructs, biochemical assays, phylogenetic analysis","journal":"Molecular biology and evolution","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis with functional readout, but limited functional validation details in abstract, single lab","pmids":["21705382"],"is_preprint":false},{"year":2001,"finding":"Human Boo/Diva (BCL2L10) is not exclusively localized to mitochondria before apoptosis induction; EGFP-Boo/Diva translocates to mitochondria during vincristine-induced apoptosis. Overexpression of human Boo/Diva promoted cell death in HeLa and 293 cells. Bcl-XL interacts with Boo but cannot protect cells from Boo/Diva-induced cell death.","method":"GFP-fusion live imaging, co-immunoprecipitation, overexpression apoptosis assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live imaging of translocation, Co-IP, functional overexpression assay, single lab with multiple methods","pmids":["11566354"],"is_preprint":false},{"year":2001,"finding":"In human glioma cells, Diva/Boo (BCL2L10) inhibits apoptosis induced by CD95 ligand or chemotherapeutic drugs, and interferes with apoptotic signaling downstream of cytochrome c release but upstream of caspase activation, consistent with inhibition of the apoptosome/Apaf-1.","method":"Overexpression assays, apoptosis induction with multiple stimuli, cytochrome c release and caspase activation measurements","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement by epistasis (downstream of cytochrome c, upstream of caspase), multiple apoptotic stimuli, single lab","pmids":["11557035"],"is_preprint":false},{"year":2013,"finding":"BCL-B promotes lung cancer invasiveness by direct interaction with the effector protein BOK; this interaction promotes sublethal MOMP generating apoptosis-flatliners that become drug-tolerant persister cells, and engages EMT to enhance cancer cell invasiveness.","method":"Co-immunoprecipitation, MOMP assays, drug-tolerant persister cell characterization, EMT marker analysis","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of BCL-B with BOK, functional MOMP assays, single lab with multiple readouts","pmids":["39996719"],"is_preprint":false}],"current_model":"BCL2L10 (Boo/BCL-B) is an anti-apoptotic BCL-2 family member that inhibits the mitochondrial apoptosis pathway by: (1) selectively binding Bax (via Bax's BH3 domain) but not Bak to suppress Bax-mediated apoptosis; (2) interacting with Apaf-1 to suppress apoptosome formation; (3) binding the IP3 receptor via its BH4 domain at the ER to inhibit Ca2+ release, with this activity antagonized by IRBIT at MAMs; (4) inhibiting autophagy by binding BECN1 and blocking its interaction with PI3KC3; (5) suppressing mitophagy by binding and inhibiting phospho-Parkin; (6) interacting with BOK to promote sublethal MOMP; (7) undergoing K48-linked polyubiquitination at K128 for proteasomal degradation, regulated by Ubiquilin1 and UBQLN4; (8) undergoing phenotypic conversion from anti- to pro-apoptotic by binding to Nur77/TR3; (9) playing roles in oocyte maturation and meiotic spindle assembly through interaction with Tpx2 and regulation of Aurora kinase A; and (10) having its transcription regulated by STAT3."},"narrative":{"mechanistic_narrative":"BCL2L10 (Boo/Diva/Bcl-B/Nrh) is an anti-apoptotic BCL-2 family protein that restrains the mitochondrial (intrinsic) death pathway and integrates apoptosis with autophagy and Ca2+ signaling [PMID:11278245, PMID:11689480]. It localizes to intracellular membranes through its hydrophobic C-terminal transmembrane domain, which is required for organelle association and full anti-apoptotic activity [PMID:9878060, PMID:11278245], and blocks cytochrome c release, mitochondrial membrane potential collapse, and caspase-3 activation while sparing death-receptor (TNFα/CD95) signaling [PMID:11689480, PMID:11557035]. Its defining biochemical feature is selectivity: it binds and suppresses Bax but not Bak, recognizing the BH3 domain of Bax through a structurally defined BH3-binding pocket, and engages a restricted set of BH3-only partners (Bim and Bik) [PMID:12921534, PMID:23235460]. A crystal structure of the Bcl-B:Bim complex reveals an unstructured loop inserted between helices α5 and α6 that distinguishes it from other family members, and this region harbors an evolutionarily acquired calcium-binding motif [PMID:23235460, PMID:21705382]. Beyond direct effector neutralization, BCL2L10 acts at the ER and mitochondria-associated membranes, where its BH4 domain binds the IP3 receptor to suppress ER Ca2+ release, an activity antagonized by dephosphorylated IRBIT during apoptotic stress to promote ER-mitochondria Ca2+ transfer [PMID:27995898, PMID:29330143]. It additionally suppresses autophagy by binding the BH3 domain of Beclin-1 and displacing PI3KC3 [PMID:22498477, PMID:30696802], and dampens mitophagy by binding and inhibiting phospho-Parkin [PMID:30635551]. BCL2L10 abundance is tightly controlled by K48-linked polyubiquitination at K128 (with K119/K120) targeting it for proteasomal degradation, while the chaperone-like ubiquilins UBQLN1 and UBQLN4 selectively bind and stabilize the protein [PMID:23563182, PMID:22233804, PMID:34245648]. The protein is not a passive survival factor: the nuclear receptor Nur77/TR3 binds Bcl-B and converts it from anti- to pro-apoptotic [PMID:17227826], and its survival function is exploited in cancer, where STAT3-driven transcription confers resistance to cisplatin and ABT-737—to which BCL2L10 is intrinsically insensitive [PMID:33396645, PMID:22875003]. In oocytes, BCL2L10 associates with TPX2 and regulates Aurora kinase A to support meiotic spindle assembly and the metaphase I-to-II transition [PMID:27753540, PMID:19439730].","teleology":[{"year":1999,"claim":"Established BCL2L10 as a membrane-associated anti-apoptotic BCL-2 family member that physically engages the apoptosome, defining its first mechanistic foothold in the death pathway.","evidence":"Co-IP, pulldown and subcellular fractionation showing Boo-Apaf-1/caspase-9 complex formation and membrane localization via the C-terminus","pmids":["9878060"],"confidence":"High","gaps":["Whether Apaf-1 binding is direct or bridged was not resolved","Did not define which BH domains mediate effector versus apoptosome interactions"]},{"year":2001,"claim":"Defined the domain architecture and pathway placement, showing BCL2L10 blocks the mitochondrial pathway upstream of caspases but not death-receptor signaling, and requires its BH4 and TM domains.","evidence":"Co-IP, GST pulldown, cytochrome c/caspase-3/membrane-potential readouts and domain deletion across transfection systems","pmids":["11278245","11689480","11557035","11566354"],"confidence":"High","gaps":["Pro- versus anti-apoptotic behavior in different cell contexts left unreconciled","Structural basis for Bax-not-Bak selectivity not yet established"]},{"year":2003,"claim":"Resolved the molecular basis of Bax-selective inhibition, showing recognition of the Bax BH3 domain through a defined binding pocket whose mutation abolishes function.","evidence":"BH3-swap chimeras, alanine scanning, and structure-based pocket mutagenesis with apoptosis readouts","pmids":["12921534"],"confidence":"High","gaps":["Did not explain why Bak BH3 is excluded structurally","No co-structure provided at this stage"]},{"year":2007,"claim":"Showed BCL2L10 is not a unidirectional survival factor: Nur77/TR3 binding converts it to a pro-apoptotic effector, and identified NM23-H2 as a negative regulator of its abundance.","evidence":"Endogenous Co-IP, RNAi epistasis and fluorescence polarization (Nur77); yeast two-hybrid, Co-IP and siGN (NM23-H2)","pmids":["17227826","17532299"],"confidence":"High","gaps":["Conformational basis of the anti-to-pro-apoptotic switch unknown","NM23-H2 mechanism of down-regulation not defined as direct"]},{"year":2008,"claim":"Comparative profiling cemented Bax-over-Bak selectivity as a distinguishing property among anti-apoptotic family members and revealed insensitivity to ABT-737.","evidence":"Three independent binding assays (Co-IP, GST pulldown, fluorescence polarization with BH3 peptides) plus apoptosis assays; HIP1R interaction by Y2H/Far-Western","pmids":["18178565","19255499"],"confidence":"High","gaps":["HIP1R-induced BAK-dependent death mechanism incompletely placed","Therapeutic consequence of ABT-737 insensitivity not yet tested"]},{"year":2009,"claim":"Extended BCL2L10 function beyond apoptosis to oocyte biology, linking it to microtubule/TCTP association and meiotic progression.","evidence":"Co-IP, immunofluorescence, neutralizing-antibody and dsRNA microinjection with spindle/MPF readouts in oocytes","pmids":["19551325","19439730"],"confidence":"Medium","gaps":["Whether the meiotic role is mechanistically distinct from apoptosis suppression unclear","Single-lab oocyte system; direct partners of the spindle role undefined at this point"]},{"year":2011,"claim":"Identified an evolutionarily acquired calcium-binding motif in the α5-α6 interhelical region, foreshadowing a Ca2+-related function.","evidence":"Site-directed mutagenesis, truncation constructs and phylogenetic analysis with biochemical readouts","pmids":["21705382"],"confidence":"Medium","gaps":["Functional consequence of Ca2+ binding not demonstrated in cells","Limited functional validation in the report"]},{"year":2012,"claim":"Defined the proteostatic control of BCL2L10 and expanded its function to autophagy suppression and a defined structural fold.","evidence":"Mass spectrometry, site-specific ubiquitin mutagenesis, linkage-specific antibodies, cycloheximide chase (K128 K48-ubiquitination; UBQLN1 stabilization); Co-IP/autophagy flux (Beclin-1); 1.9 Å crystal structure with Bim","pmids":["22233804","23563182","22498477","23235460","22875003"],"confidence":"High","gaps":["The E3 ligase for K128 ubiquitination not identified","How ubiquilin stabilization and ubiquitin-driven degradation are coordinated unresolved"]},{"year":2016,"claim":"Established the ER/MAM Ca2+ axis, showing BCL2L10 inhibits the IP3 receptor and is antagonized by dephosphorylated IRBIT to license apoptosis, and linked it to meiotic spindle assembly via TPX2/Aurora A.","evidence":"Co-IP, MAM fractionation, Ca2+ imaging and phosphorylation assays (IRBIT); Co-IP, co-localization, RNAi and kinase activity assay (TPX2/Aurka)","pmids":["27995898","27753540"],"confidence":"High","gaps":["How IRBIT phosphorylation state is sensed by BCL2L10 mechanistically unclear","Aurora A regulation shown by RNAi correlation, not direct enzymatic mechanism"]},{"year":2018,"claim":"Confirmed BH4-dependent IP3R inhibition at the ER as an anti-apoptotic mechanism with therapeutic relevance, as BH4 mimetic peptides suppress tumor growth.","evidence":"Confocal localization, Co-IP, BH4-deletion mutagenesis, Ca2+ release assays and in vitro/in vivo tumor models","pmids":["29330143"],"confidence":"High","gaps":["Whether IP3R inhibition and effector sequestration act independently in tumors unclear","Specificity of BH4 mimetics for BCL2L10 over related proteins not addressed"]},{"year":2019,"claim":"Connected BCL2L10 to mitophagy and autophagy regulation in tissue contexts, showing it inhibits phospho-Parkin and displaces PI3KC3 from Beclin-1.","evidence":"Co-IP with phospho-Parkin, siRNA/overexpression with mitophagy and apoptosis assays (HSCs); Co-IP, ELISA and autophagy flux (Beclin-1/PI3KC3 in hepatoma)","pmids":["30635551","30696802"],"confidence":"Medium","gaps":["Whether Parkin inhibition is via direct dephosphorylation or steric block unresolved","Single-lab, tissue-specific findings; generality across cell types untested"]},{"year":2021,"claim":"Placed BCL2L10 in cancer drug-resistance circuits, defining STAT3 transcriptional control, UBQLN4-mediated stabilization, and a BOK interaction driving persister-cell phenotypes.","evidence":"ChIP/reporter/mutagenesis and siRNA with drug-sensitivity readouts (STAT3, melanoma); Co-IP and genetic screening (UBQLN4); Co-IP and MOMP/EMT assays (BOK, lung cancer)","pmids":["33396645","34245648","39996719"],"confidence":"Medium","gaps":["Direct versus indirect nature of BOK-driven sublethal MOMP unclear","How STAT3, ubiquilin stabilization, and degradation jointly set BCL2L10 levels in tumors not integrated"]},{"year":null,"claim":"The E3 ubiquitin ligase that drives K48/K128 turnover, the structural mechanism of the Nur77-induced anti-to-pro-apoptotic switch, and how the apoptotic, Ca2+, autophagic, and meiotic roles are coordinated in vivo remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No identified E3 ligase for BCL2L10 degradation","No structural model of the pro-apoptotic conformation","No integrated in vivo model linking the multiple cellular functions"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[4,14,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[16,18,13]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[9,17]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[16,18]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[24,9,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11,6]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,3,4]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13,20,19]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[16,18]}],"complexes":["Bcl-B:Bim complex","IRBIT-Bcl2l10 complex at MAMs","TPX2-containing meiotic spindle complex"],"partners":["BAX","BIM","BECN1","ITPR1","IRBIT","APAF1","BOK","UBQLN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9HD36","full_name":"Bcl-2-like protein 10","aliases":["Anti-apoptotic protein Boo","Anti-apoptotic protein NrH","Apoptosis regulator Bcl-B"],"length_aa":204,"mass_kda":23.2,"function":"Promotes cell survival by suppressing apoptosis induced by BAX but not BAK (PubMed:11278245, PubMed:11689480). Increases binding of AHCYL1/IRBIT to ITPR1 (PubMed:27995898). Reduces ITPR1-mediated calcium release from the endoplasmic reticulum cooperatively with AHCYL1/IRBIT under normal cellular conditions (PubMed:27995898). Under apoptotic stress conditions, dissociates from ITPR1 and is displaced from mitochondria-associated endoplasmic reticulum membranes, leading to increased Ca(2+) transfer to mitochondria which promotes apoptosis (PubMed:27995898). Required for the correct formation of the microtubule organizing center during oocyte cell division, potentially via regulation of protein abundance and localization of other microtubule organizing center components such as AURKA and TPX2 (By similarity)","subcellular_location":"Mitochondrion; Nucleus membrane; Endoplasmic reticulum; Cytoplasm, cytoskeleton, spindle","url":"https://www.uniprot.org/uniprotkb/Q9HD36/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL2L10","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL2L10","total_profiled":1310},"omim":[{"mim_id":"606910","title":"BCL2-LIKE 10; BCL2L10","url":"https://www.omim.org/entry/606910"},{"mim_id":"254500","title":"MYELOMA, MULTIPLE","url":"https://www.omim.org/entry/254500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":9.2},{"tissue":"skin 1","ntpm":6.5}],"url":"https://www.proteinatlas.org/search/BCL2L10"},"hgnc":{"alias_symbol":["Diva","Boo","BCL-B"],"prev_symbol":[]},"alphafold":{"accession":"Q9HD36","domains":[{"cath_id":"1.10.437.10","chopping":"13-173","consensus_level":"high","plddt":90.487,"start":13,"end":173},{"cath_id":"1.20.5","chopping":"176-204","consensus_level":"medium","plddt":79.3924,"start":176,"end":204}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HD36","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HD36-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HD36-F1-predicted_aligned_error_v6.png","plddt_mean":85.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL2L10","jax_strain_url":"https://www.jax.org/strain/search?query=BCL2L10"},"sequence":{"accession":"Q9HD36","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HD36.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HD36/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HD36"}},"corpus_meta":[{"pmid":"9878060","id":"PMC_9878060","title":"Boo, a novel negative regulator of cell death, interacts with Apaf-1.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9878060","citation_count":143,"is_preprint":false},{"pmid":"18178565","id":"PMC_18178565","title":"Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18178565","citation_count":114,"is_preprint":false},{"pmid":"11278245","id":"PMC_11278245","title":"Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278245","citation_count":104,"is_preprint":false},{"pmid":"22875003","id":"PMC_22875003","title":"Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22875003","citation_count":74,"is_preprint":false},{"pmid":"22577154","id":"PMC_22577154","title":"BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.","date":"2012","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/22577154","citation_count":71,"is_preprint":false},{"pmid":"17227826","id":"PMC_17227826","title":"Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17227826","citation_count":71,"is_preprint":false},{"pmid":"27995898","id":"PMC_27995898","title":"IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27995898","citation_count":62,"is_preprint":false},{"pmid":"22233804","id":"PMC_22233804","title":"Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22233804","citation_count":62,"is_preprint":false},{"pmid":"23235460","id":"PMC_23235460","title":"The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23235460","citation_count":61,"is_preprint":false},{"pmid":"11689480","id":"PMC_11689480","title":"Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11689480","citation_count":59,"is_preprint":false},{"pmid":"30635551","id":"PMC_30635551","title":"The role of the apoptosis-related protein BCL-B in the regulation of mitophagy in hepatic stellate cells during the regression of liver fibrosis.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30635551","citation_count":51,"is_preprint":false},{"pmid":"18483366","id":"PMC_18483366","title":"Bcl-B expression in human epithelial and nonepithelial malignancies.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18483366","citation_count":50,"is_preprint":false},{"pmid":"22498477","id":"PMC_22498477","title":"The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death.","date":"2012","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/22498477","citation_count":44,"is_preprint":false},{"pmid":"19551325","id":"PMC_19551325","title":"Oocytes and early embryos selectively express the survival factor BCL2L10.","date":"2009","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/19551325","citation_count":37,"is_preprint":false},{"pmid":"29330143","id":"PMC_29330143","title":"Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29330143","citation_count":36,"is_preprint":false},{"pmid":"17532299","id":"PMC_17532299","title":"NM23-H2 involves in negative regulation of Diva and Bcl2L10 in apoptosis signaling.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17532299","citation_count":35,"is_preprint":false},{"pmid":"21171085","id":"PMC_21171085","title":"BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21171085","citation_count":34,"is_preprint":false},{"pmid":"11566354","id":"PMC_11566354","title":"Characterization of NR13-related human cell death regulator, Boo/Diva, in normal and cancer tissues.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11566354","citation_count":32,"is_preprint":false},{"pmid":"12921534","id":"PMC_12921534","title":"Characterization of the anti-apoptotic mechanism of Bcl-B.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12921534","citation_count":31,"is_preprint":false},{"pmid":"19439730","id":"PMC_19439730","title":"Role of Bcl2-like 10 (Bcl2l10) in Regulating Mouse Oocyte Maturation.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19439730","citation_count":30,"is_preprint":false},{"pmid":"20919753","id":"PMC_20919753","title":"Homology modeling and docking studies of human Bcl-2L10 protein.","date":"2010","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/20919753","citation_count":27,"is_preprint":false},{"pmid":"34311189","id":"PMC_34311189","title":"The roles of MCP-1/CCR2 mediated macrophage recruitment and polarization in bladder outlet obstruction (BOO) induced bladder remodeling.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34311189","citation_count":24,"is_preprint":false},{"pmid":"27455953","id":"PMC_27455953","title":"BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27455953","citation_count":23,"is_preprint":false},{"pmid":"19255499","id":"PMC_19255499","title":"HIP1R interacts with a member of Bcl-2 family, BCL2L10, and induces BAK-dependent cell death.","date":"2009","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19255499","citation_count":22,"is_preprint":false},{"pmid":"20428828","id":"PMC_20428828","title":"BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer.","date":"2010","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20428828","citation_count":22,"is_preprint":false},{"pmid":"24047476","id":"PMC_24047476","title":"The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.","date":"2013","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/24047476","citation_count":21,"is_preprint":false},{"pmid":"33396645","id":"PMC_33396645","title":"BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33396645","citation_count":19,"is_preprint":false},{"pmid":"27770580","id":"PMC_27770580","title":"BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.","date":"2016","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27770580","citation_count":18,"is_preprint":false},{"pmid":"30519035","id":"PMC_30519035","title":"MicroRNA-18a promotes hepatocellular carcinoma proliferation, migration, and invasion by targeting Bcl2L10.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30519035","citation_count":18,"is_preprint":false},{"pmid":"35005368","id":"PMC_35005368","title":"Boo-boos as the building blocks of pain expression: An observational examination of parental responses to everyday pain in toddlers.","date":"2018","source":"Canadian journal of pain = Revue canadienne de la douleur","url":"https://pubmed.ncbi.nlm.nih.gov/35005368","citation_count":17,"is_preprint":false},{"pmid":"30696802","id":"PMC_30696802","title":"BCL2L10/BECN1 modulates hepatoma cells autophagy by regulating PI3K/AKT signaling pathway.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/30696802","citation_count":16,"is_preprint":false},{"pmid":"23563182","id":"PMC_23563182","title":"Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23563182","citation_count":16,"is_preprint":false},{"pmid":"11557035","id":"PMC_11557035","title":"Diva/Boo is a negative regulator of cell death in human glioma cells.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11557035","citation_count":16,"is_preprint":false},{"pmid":"30549198","id":"PMC_30549198","title":"MicroRNA-101 protects bladder of BOO from hypoxia-induced fibrosis by attenuating TGF-β-smad2/3 signaling.","date":"2018","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/30549198","citation_count":14,"is_preprint":false},{"pmid":"37899453","id":"PMC_37899453","title":"Bcl-B: an \"unknown\" protein of the Bcl-2 family.","date":"2023","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/37899453","citation_count":13,"is_preprint":false},{"pmid":"21705382","id":"PMC_21705382","title":"Characterization of unique signature sequences in the divergent maternal protein Bcl2l10.","date":"2011","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/21705382","citation_count":11,"is_preprint":false},{"pmid":"34245648","id":"PMC_34245648","title":"UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34245648","citation_count":10,"is_preprint":false},{"pmid":"18626112","id":"PMC_18626112","title":"A TR3/Nur77 peptide-based high-throughput fluorescence polarization screen for small molecule Bcl-B inhibitors.","date":"2008","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/18626112","citation_count":10,"is_preprint":false},{"pmid":"31894274","id":"PMC_31894274","title":"Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.","date":"2019","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31894274","citation_count":9,"is_preprint":false},{"pmid":"34232473","id":"PMC_34232473","title":"BOO induces fibrosis and EMT in urothelial cells which can be recapitulated in vitro through elevated storage and voiding pressure cycles.","date":"2021","source":"International urology and nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/34232473","citation_count":9,"is_preprint":false},{"pmid":"32468047","id":"PMC_32468047","title":"Urethral meatus stricture BOO stimulates bladder smooth muscle cell proliferation and pyroptosis via IL‑1β and the SGK1‑NFAT2 signaling pathway.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32468047","citation_count":9,"is_preprint":false},{"pmid":"23293224","id":"PMC_23293224","title":"Subcellular dynamics of the maternal cell death regulator BCL2L10 in human preimplantation embryos.","date":"2013","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23293224","citation_count":8,"is_preprint":false},{"pmid":"32477400","id":"PMC_32477400","title":"Severe Phenotype in a Patient With Homozygous 15q21.2 Microdeletion Involving BCL2L10, GNB5, and MYO5C Genes, Resembling Infantile Developmental Disorder With Cardiac Arrhythmias (IDDCA).","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32477400","citation_count":8,"is_preprint":false},{"pmid":"33649794","id":"PMC_33649794","title":"Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33649794","citation_count":7,"is_preprint":false},{"pmid":"27753540","id":"PMC_27753540","title":"Bcl2l10, a new Tpx2 binding partner, is a master regulator of Aurora kinase A in mouse oocytes.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/27753540","citation_count":6,"is_preprint":false},{"pmid":"29331495","id":"PMC_29331495","title":"Role of BCL2L10 in regulating buffalo (Bubalus bubalis) oocyte maturation.","date":"2017","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/29331495","citation_count":5,"is_preprint":false},{"pmid":"15518177","id":"PMC_15518177","title":"Effect of Boo Yong-Tang on mast cell-mediated allergic reaction.","date":"2004","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/15518177","citation_count":5,"is_preprint":false},{"pmid":"23192964","id":"PMC_23192964","title":"Nuclear magnetic resonance study of protein-protein interactions involving apoptosis regulator Diva (Boo) and the BH3 domain of proapoptotic Bcl-2 members.","date":"2012","source":"Journal of molecular recognition : JMR","url":"https://pubmed.ncbi.nlm.nih.gov/23192964","citation_count":4,"is_preprint":false},{"pmid":"36341977","id":"PMC_36341977","title":"Expression patterns and biological function of BCL2L10 during mouse preimplantation development.","date":"2022","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/36341977","citation_count":3,"is_preprint":false},{"pmid":"38111145","id":"PMC_38111145","title":"Molecular dynamics simulations assisted investigation of phytochemicals as potential lead candidates against anti-apoptotic Bcl-B protein.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/38111145","citation_count":3,"is_preprint":false},{"pmid":"34512021","id":"PMC_34512021","title":"circTADA2A Retards the Progression of Colorectal Cancer via Regulating miR-1229/BCL2L10 Signal Axis.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/34512021","citation_count":2,"is_preprint":false},{"pmid":"29403616","id":"PMC_29403616","title":"Asymptomatic bacteriuria in pregnant women attending Boo-Ali Hospital Tehran Iran: Urine analysis vs. urine culture.","date":"2017","source":"Electronic physician","url":"https://pubmed.ncbi.nlm.nih.gov/29403616","citation_count":2,"is_preprint":false},{"pmid":"20127209","id":"PMC_20127209","title":"Sequence-specific 1H, 13C, and 15N resonance assignments of Diva (Boo), an apoptosis regulator of the Bcl-2 family.","date":"2010","source":"Biomolecular NMR assignments","url":"https://pubmed.ncbi.nlm.nih.gov/20127209","citation_count":2,"is_preprint":false},{"pmid":"40296623","id":"PMC_40296623","title":"HuangE Capsules Improve Bladder Function in BOO-induced Overactive Bladder Rats: Network Pharmacology and Experimental Validation.","date":"2025","source":"Combinatorial chemistry & high throughput screening","url":"https://pubmed.ncbi.nlm.nih.gov/40296623","citation_count":1,"is_preprint":false},{"pmid":"39996719","id":"PMC_39996719","title":"BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOK.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/39996719","citation_count":1,"is_preprint":false},{"pmid":"36393846","id":"PMC_36393846","title":"Survivin knockdown alleviates pathological hydrostatic pressure-induced bladder smooth muscle cell dysfunction and BOO-induced bladder remodeling via autophagy.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36393846","citation_count":1,"is_preprint":false},{"pmid":"39884007","id":"PMC_39884007","title":"Withania somnifera-derived phytochemicals as Bcl-B inhibitors in cancer therapy: A computational approach from byte to bench to bedside.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39884007","citation_count":1,"is_preprint":false},{"pmid":"40941785","id":"PMC_40941785","title":"Pectin Peek-a-Boo: Homogalacturonan Turnover During Flooding-Induced Legume Root Aerenchyma Formation.","date":"2025","source":"Plants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40941785","citation_count":0,"is_preprint":false},{"pmid":"41559677","id":"PMC_41559677","title":"Urothelial Piezo1 channel contributes to BOO-induced inflammation, EMT, and bladder fibrosis via activation of NLRP3 inflammasome.","date":"2026","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41559677","citation_count":0,"is_preprint":false},{"pmid":"37664460","id":"PMC_37664460","title":"Retraction: Survivin knockdown alleviates pathological hydrostatic pressure-induced bladder smooth muscle cell dysfunction and BOO-induced bladder remodeling via autophagy.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37664460","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.09.25339598","title":"Third dose COVID-19 vaccination elicits immune memory in patients with inborn errors of immunity even in absence of neutralizing antibodies","date":"2025-11-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.09.25339598","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":31780,"output_tokens":6610,"usd":0.097245,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15474,"output_tokens":4753,"usd":0.098098,"stage2_stop_reason":"end_turn"},"total_usd":0.195343,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Boo (BCL2L10) interacts with Apaf-1 and forms a multimeric protein complex with Apaf-1 and caspase-9; pro-apoptotic Bak and Bik disrupt the Boo-Apaf-1 association. Boo also binds three distinct regions of Apaf-1.\",\n      \"method\": \"Co-immunoprecipitation, pulldown assays, transfection-based apoptosis assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with multiple binding partners, disruption by pro-apoptotic proteins, replicated with multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"9878060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Boo (BCL2L10) localizes to intracellular membranes via its hydrophobic C-terminus and inhibits apoptosis; it homodimerizes and heterodimerizes with other Bcl-2 family members.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation, transfection-based apoptosis assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — localization by fractionation tied to function, dimerization by Co-IP, multiple orthogonal methods\",\n      \"pmids\": [\"9878060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Bcl-B (BCL2L10) contains BH1, BH2, BH3, BH4, and a C-terminal transmembrane domain; it binds Bcl-2, Bcl-XL, and Bax but NOT Bak. It suppresses Bax-induced but not Bak-induced apoptosis. Deletion of the TM domain impairs association with intracellular organelles and diminishes anti-apoptotic function.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transient transfection apoptosis assays, domain deletion mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, functional mutagenesis (TM deletion), multiple orthogonal methods in one study\",\n      \"pmids\": [\"11278245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Bcl2-L-10 blocks apoptosis in the mitochondrial death pathway (preventing cytochrome C release, caspase-3 activation, and mitochondrial membrane potential collapse) but does not block TNFα-induced (death receptor) apoptosis. Both the BH4 domain and transmembrane domain are necessary for its anti-apoptotic function.\",\n      \"method\": \"Transfection assays, cytochrome C release measurement, caspase-3 activation assay, mitochondrial membrane potential assay, domain deletion mutagenesis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal functional readouts, domain mutagenesis establishing necessary elements, pathway placement by comparison with death receptor pathway\",\n      \"pmids\": [\"11689480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Bcl-B selectively binds Bax over Bak via the BH3 domain of Bax; chimeric Bak containing Bax's BH3 domain bound Bcl-B whereas chimeric Bax containing Bak's BH3 domain did not. Alanine-scanning of Bax BH3 and structure-based mutations in Bcl-B's BH3-binding pocket (L86A and R96Q) abolished Bax binding and apoptosis suppression, confirming binding-dependent suppression mechanism.\",\n      \"method\": \"BH3-swap chimeric mutant co-immunoprecipitation, alanine-scanning mutagenesis, structure-based mutagenesis of BH3-binding pocket, transient transfection apoptosis assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro mutagenesis with functional readouts, multiple orthogonal approaches establishing molecular basis of selectivity\",\n      \"pmids\": [\"12921534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nuclear receptor Nur77/TR3 selectively binds Bcl-B among anti-apoptotic Bcl-2 family members and converts Bcl-B from anti-apoptotic to pro-apoptotic. Endogenous Bcl-B associates with endogenous Nur77 in RPMI 8226 myeloma cells, and RNAi knockdown of Bcl-B demonstrated dependence on Bcl-B for Nur77-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, RNAi knockdown, fluorescence polarization binding assay, peptide treatment assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — endogenous Co-IP, RNAi epistasis, binding specificity profiled across all 6 family members, multiple orthogonal methods\",\n      \"pmids\": [\"17227826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NM23-H2 interacts with Diva/BCL2L10 (requiring the transmembrane domain of Diva) and co-localizes in cytoplasm. NM23-H2 overexpression down-regulates Diva protein level; NM23-H2 knockdown restores Diva expression and increases Diva-mediated apoptotic activity.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, subcellular co-localization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain requirement, siRNA functional validation, single lab with two orthogonal methods\",\n      \"pmids\": [\"17532299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Bcl-B shows strong preference for binding and suppressing Bax over Bak, in contrast to Bcl-2, Bcl-XL, Bcl-W, and Bfl-1 which bind both. Bcl-B is not targeted by ABT-737 due to low affinity.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, fluorescence polarization with synthetic BH3 peptides, transient transfection apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent binding methods plus functional assays, comparative profiling across all anti-apoptotic family members\",\n      \"pmids\": [\"18178565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"HIP1R interacts with BCL2L10 (requiring both ANTH and THATCH domains of HIP1R); HIP1R overexpression induces cell death dependent on BAK (not BAX), associated with mitochondrial membrane potential loss and caspase-9 activation, and augments BCL2L10-caspase-9 association.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, Far-Western analysis, domain deletion, caspase-9 activation assay, mitochondrial membrane potential assay\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirmed by Far-Western, domain mapping, functional phenotype, single lab\",\n      \"pmids\": [\"19255499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BCL2L10 protein is associated with the microtubule binding protein TCTP (translationally controlled tumor protein) and with mitochondria in oocytes, with stage-specific redistribution along the pericortical regulatory ooplasm. Neutralization of BCL2L10 accelerated oocyte death.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, neutralizing antibody treatment, subcellular fractionation\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and localization imaging with functional consequence (neutralization accelerates death), single lab\",\n      \"pmids\": [\"19551325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Bcl2l10 RNAi in mouse germinal vesicle oocytes causes metaphase I arrest with spindle and chromosome abnormalities; Bcl2l10 affects maturation-promoting factor activity but not MAPK activity at the MI-MII transition.\",\n      \"method\": \"Microinjection of dsRNA, immunofluorescence for spindle/chromosomes, MPF and MAPK activity assays\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi loss-of-function with specific cellular phenotype and pathway placement, single lab\",\n      \"pmids\": [\"19439730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCL2L10 (BCLb) protein stability is regulated by Ubiquilin1 (Ubqln1), which specifically interacts with BCLb (but not other anti-apoptotic BCL2 family members), stabilizes BCLb protein, promotes its monoubiquitination on multiple lysine residues, and relocalizes it to the cytosol.\",\n      \"method\": \"Immunoaffinity purification, mass spectrometry, cycloheximide chase, co-immunoprecipitation, ubiquitination assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mass spectrometry identification confirmed by Co-IP, functional stability assay, specificity demonstrated across family members, multiple orthogonal methods\",\n      \"pmids\": [\"22233804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Bcl-B is polyubiquitinated at steady state via K48-linked chains; K128 is the primary acceptor site (confirmed by mass spectrometry and linkage-specific antibodies), with K119 and K120 as additional sites. Ubiquitination targets Bcl-B for proteasomal degradation and controls its anti-apoptotic capacity. A lysineless Bcl-B mutant shows 5-fold higher protein expression than wild-type.\",\n      \"method\": \"Mutagenesis (lysine substitutions), mass spectrometry, linkage-specific ubiquitin antibodies, proteasome inhibition, cycloheximide chase\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-specific mutagenesis, MS confirmation of ubiquitination site, linkage-specific antibodies, multiple orthogonal methods in one study\",\n      \"pmids\": [\"23563182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Bcl-B interacts with the BH3 domain of BECN1 (Beclin-1) and inhibits autophagy; Bcl-B overexpression reduces autophagy triggered by various stimuli while Bcl-B knockdown triggers autophagic cell death dependent on LC3, BECN1, and ATG5.\",\n      \"method\": \"Co-immunoprecipitation, autophagy flux assays, siRNA knockdown, overexpression studies\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of endogenous proteins, RNAi with specific autophagy pathway dependency, single lab with two orthogonal methods\",\n      \"pmids\": [\"22498477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Bcl-B has high-affinity interactions with Bim and Bik BH3-only proteins only; it does not bind other BH3-only proteins with high affinity. Crystal structure of Bcl-B:Bim complex resolved to 1.9 Å reveals an insertion of an unstructured loop between helices α5 and α6 distinguishing Bcl-B from other family members.\",\n      \"method\": \"X-ray crystallography (1.9 Å resolution), fluorescence polarization binding assays, cell-based apoptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with biophysical binding assays and cell-based functional validation, comprehensive BH3-only protein profiling\",\n      \"pmids\": [\"23235460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Bcl-B is not targeted by ABT-737 (low affinity), in contrast to Bcl-2, Bcl-xL, and Bcl-w. Noxa, but not Bim, Puma, or truncated Bid, can overcome Bcl-B-mediated resistance to ABT-737.\",\n      \"method\": \"Inducible expression system, cell-based apoptosis assays with BH3-only protein expression, drug treatment experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional epistasis with inducible expression, single lab, clear mechanistic result on selectivity\",\n      \"pmids\": [\"22875003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IRBIT interacts with Bcl2l10 and they additively inhibit IP3R in the physiological state. Upon apoptotic stress, IRBIT is dephosphorylated and becomes an inhibitor of Bcl2l10. The IRBIT-Bcl2l10 complex associates in mitochondria-associated membranes (MAMs); IRBIT promotes ER-mitochondria contact and facilitates Ca2+ transfer to mitochondria to promote apoptosis by inhibiting Bcl2l10.\",\n      \"method\": \"Co-immunoprecipitation, IP3R activity assays, phosphorylation assays, subcellular fractionation (MAM isolation), Ca2+ imaging, IRBIT knockdown\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including biochemical reconstitution in MAMs, Ca2+ functional assays, phosphorylation state dependency, mechanistic model with multiple supporting experiments\",\n      \"pmids\": [\"27995898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Bcl2l10 co-localizes on meiotic spindles with Tpx2 and Aurora kinase A (Aurka); Bcl2l10 is present in the same complex as Tpx2. Bcl2l10 RNAi decreases Tpx2 and Aurka expression while increasing phospho-Aurka, resulting in decreased Aurka catalytic activity, disrupted MTOC formation, and impaired meiotic spindle assembly.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, RNAi, kinase activity assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and co-localization, RNAi with kinase activity readout, single lab with multiple methods\",\n      \"pmids\": [\"27753540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Nrh/BCL2L10 localizes to the endoplasmic reticulum and makes BH4 domain-dependent interactions with the ligand-binding domain of IP3R (type 1/3 Ca2+ channel), negatively regulating ER-Ca2+ release to mediate anti-apoptosis. Disrupting Nrh/IP3R complexes with BH4 mimetic peptides inhibits breast cancer cell growth in vitro and in vivo.\",\n      \"method\": \"Immunofluorescence/confocal localization, co-immunoprecipitation, BH4-domain deletion mutagenesis, Ca2+ release assays, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — domain mutagenesis, Co-IP, functional Ca2+ assays, in vivo validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"29330143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCL-B binds phospho-Parkin directly and inhibits its phosphorylation, thereby suppressing mitophagy in hepatic stellate cells. BCL-B knockdown increases both mitophagy and apoptosis in HSCs, while BCL-B overexpression has the opposite effects.\",\n      \"method\": \"Co-immunoprecipitation of BCL-B with phospho-Parkin, siRNA knockdown, overexpression, mitophagy assays, apoptosis assays\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with phospho-Parkin, bidirectional gain/loss-of-function with specific mitophagy phenotype, single lab\",\n      \"pmids\": [\"30635551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCL2L10 interacts with BECN1 (Beclin-1) in hepatoma cells; this interaction reduces the association between BECN1 and PI3KC3, thereby suppressing autophagy via the PI3K/AKT signaling pathway.\",\n      \"method\": \"Co-immunoprecipitation, ELISA, immunofluorescence co-localization, autophagic flux monitoring (LC3B-II/P62), PI3K/AKT pathway analysis\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing competitive binding between BCL2L10-BECN1 and BECN1-PI3KC3, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30696802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL2L10 expression is driven by STAT3-mediated transcription; functional STAT3 responsive elements were identified in the BCL2L10 promoter. BCL2L10 confers resistance to cisplatin, dacarbazine, and ABT-737 in melanoma; genetic and pharmacological inhibition of BCL2L10 sensitized cells to cisplatin and ABT-737.\",\n      \"method\": \"Reporter assays, site-directed mutagenesis of STAT3 binding sites, ChIP analysis, siRNA knockdown, pharmacological inhibition\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter assays, and mutagenesis for transcriptional regulation; functional siRNA with drug sensitivity readouts, single lab\",\n      \"pmids\": [\"33396645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"UBQLN4 interacts with and stabilizes BCL2L10, preventing mesothelioma cell apoptosis in response to DNA damage. UBQLN4 itself is a substrate of ATM kinase.\",\n      \"method\": \"Co-immunoprecipitation, functional genetic screening, apoptosis assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP interaction with functional consequence, genetic screening context, single lab\",\n      \"pmids\": [\"34245648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human BCL2L10 has evolved a calcium-binding motif in its α5-α6 interhelical region through acquisition of critical negatively charged residues. Deletion of the N-terminal extension had no significant functional impact in HeLa cells, but the interhelical region mutation affects function.\",\n      \"method\": \"Site-directed mutagenesis, truncation constructs, biochemical assays, phylogenetic analysis\",\n      \"journal\": \"Molecular biology and evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis with functional readout, but limited functional validation details in abstract, single lab\",\n      \"pmids\": [\"21705382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human Boo/Diva (BCL2L10) is not exclusively localized to mitochondria before apoptosis induction; EGFP-Boo/Diva translocates to mitochondria during vincristine-induced apoptosis. Overexpression of human Boo/Diva promoted cell death in HeLa and 293 cells. Bcl-XL interacts with Boo but cannot protect cells from Boo/Diva-induced cell death.\",\n      \"method\": \"GFP-fusion live imaging, co-immunoprecipitation, overexpression apoptosis assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging of translocation, Co-IP, functional overexpression assay, single lab with multiple methods\",\n      \"pmids\": [\"11566354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In human glioma cells, Diva/Boo (BCL2L10) inhibits apoptosis induced by CD95 ligand or chemotherapeutic drugs, and interferes with apoptotic signaling downstream of cytochrome c release but upstream of caspase activation, consistent with inhibition of the apoptosome/Apaf-1.\",\n      \"method\": \"Overexpression assays, apoptosis induction with multiple stimuli, cytochrome c release and caspase activation measurements\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement by epistasis (downstream of cytochrome c, upstream of caspase), multiple apoptotic stimuli, single lab\",\n      \"pmids\": [\"11557035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BCL-B promotes lung cancer invasiveness by direct interaction with the effector protein BOK; this interaction promotes sublethal MOMP generating apoptosis-flatliners that become drug-tolerant persister cells, and engages EMT to enhance cancer cell invasiveness.\",\n      \"method\": \"Co-immunoprecipitation, MOMP assays, drug-tolerant persister cell characterization, EMT marker analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of BCL-B with BOK, functional MOMP assays, single lab with multiple readouts\",\n      \"pmids\": [\"39996719\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL2L10 (Boo/BCL-B) is an anti-apoptotic BCL-2 family member that inhibits the mitochondrial apoptosis pathway by: (1) selectively binding Bax (via Bax's BH3 domain) but not Bak to suppress Bax-mediated apoptosis; (2) interacting with Apaf-1 to suppress apoptosome formation; (3) binding the IP3 receptor via its BH4 domain at the ER to inhibit Ca2+ release, with this activity antagonized by IRBIT at MAMs; (4) inhibiting autophagy by binding BECN1 and blocking its interaction with PI3KC3; (5) suppressing mitophagy by binding and inhibiting phospho-Parkin; (6) interacting with BOK to promote sublethal MOMP; (7) undergoing K48-linked polyubiquitination at K128 for proteasomal degradation, regulated by Ubiquilin1 and UBQLN4; (8) undergoing phenotypic conversion from anti- to pro-apoptotic by binding to Nur77/TR3; (9) playing roles in oocyte maturation and meiotic spindle assembly through interaction with Tpx2 and regulation of Aurora kinase A; and (10) having its transcription regulated by STAT3.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL2L10 (Boo/Diva/Bcl-B/Nrh) is an anti-apoptotic BCL-2 family protein that restrains the mitochondrial (intrinsic) death pathway and integrates apoptosis with autophagy and Ca2+ signaling [#2, #3]. It localizes to intracellular membranes through its hydrophobic C-terminal transmembrane domain, which is required for organelle association and full anti-apoptotic activity [#1, #2], and blocks cytochrome c release, mitochondrial membrane potential collapse, and caspase-3 activation while sparing death-receptor (TNFα/CD95) signaling [#3, #25]. Its defining biochemical feature is selectivity: it binds and suppresses Bax but not Bak, recognizing the BH3 domain of Bax through a structurally defined BH3-binding pocket, and engages a restricted set of BH3-only partners (Bim and Bik) [#4, #14]. A crystal structure of the Bcl-B:Bim complex reveals an unstructured loop inserted between helices α5 and α6 that distinguishes it from other family members, and this region harbors an evolutionarily acquired calcium-binding motif [#14, #23]. Beyond direct effector neutralization, BCL2L10 acts at the ER and mitochondria-associated membranes, where its BH4 domain binds the IP3 receptor to suppress ER Ca2+ release, an activity antagonized by dephosphorylated IRBIT during apoptotic stress to promote ER-mitochondria Ca2+ transfer [#16, #18]. It additionally suppresses autophagy by binding the BH3 domain of Beclin-1 and displacing PI3KC3 [#13, #20], and dampens mitophagy by binding and inhibiting phospho-Parkin [#19]. BCL2L10 abundance is tightly controlled by K48-linked polyubiquitination at K128 (with K119/K120) targeting it for proteasomal degradation, while the chaperone-like ubiquilins UBQLN1 and UBQLN4 selectively bind and stabilize the protein [#12, #11, #22]. The protein is not a passive survival factor: the nuclear receptor Nur77/TR3 binds Bcl-B and converts it from anti- to pro-apoptotic [#5], and its survival function is exploited in cancer, where STAT3-driven transcription confers resistance to cisplatin and ABT-737—to which BCL2L10 is intrinsically insensitive [#21, #15]. In oocytes, BCL2L10 associates with TPX2 and regulates Aurora kinase A to support meiotic spindle assembly and the metaphase I-to-II transition [#17, #10].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established BCL2L10 as a membrane-associated anti-apoptotic BCL-2 family member that physically engages the apoptosome, defining its first mechanistic foothold in the death pathway.\",\n      \"evidence\": \"Co-IP, pulldown and subcellular fractionation showing Boo-Apaf-1/caspase-9 complex formation and membrane localization via the C-terminus\",\n      \"pmids\": [\"9878060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Apaf-1 binding is direct or bridged was not resolved\", \"Did not define which BH domains mediate effector versus apoptosome interactions\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the domain architecture and pathway placement, showing BCL2L10 blocks the mitochondrial pathway upstream of caspases but not death-receptor signaling, and requires its BH4 and TM domains.\",\n      \"evidence\": \"Co-IP, GST pulldown, cytochrome c/caspase-3/membrane-potential readouts and domain deletion across transfection systems\",\n      \"pmids\": [\"11278245\", \"11689480\", \"11557035\", \"11566354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pro- versus anti-apoptotic behavior in different cell contexts left unreconciled\", \"Structural basis for Bax-not-Bak selectivity not yet established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the molecular basis of Bax-selective inhibition, showing recognition of the Bax BH3 domain through a defined binding pocket whose mutation abolishes function.\",\n      \"evidence\": \"BH3-swap chimeras, alanine scanning, and structure-based pocket mutagenesis with apoptosis readouts\",\n      \"pmids\": [\"12921534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not explain why Bak BH3 is excluded structurally\", \"No co-structure provided at this stage\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed BCL2L10 is not a unidirectional survival factor: Nur77/TR3 binding converts it to a pro-apoptotic effector, and identified NM23-H2 as a negative regulator of its abundance.\",\n      \"evidence\": \"Endogenous Co-IP, RNAi epistasis and fluorescence polarization (Nur77); yeast two-hybrid, Co-IP and siGN (NM23-H2)\",\n      \"pmids\": [\"17227826\", \"17532299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational basis of the anti-to-pro-apoptotic switch unknown\", \"NM23-H2 mechanism of down-regulation not defined as direct\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Comparative profiling cemented Bax-over-Bak selectivity as a distinguishing property among anti-apoptotic family members and revealed insensitivity to ABT-737.\",\n      \"evidence\": \"Three independent binding assays (Co-IP, GST pulldown, fluorescence polarization with BH3 peptides) plus apoptosis assays; HIP1R interaction by Y2H/Far-Western\",\n      \"pmids\": [\"18178565\", \"19255499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HIP1R-induced BAK-dependent death mechanism incompletely placed\", \"Therapeutic consequence of ABT-737 insensitivity not yet tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended BCL2L10 function beyond apoptosis to oocyte biology, linking it to microtubule/TCTP association and meiotic progression.\",\n      \"evidence\": \"Co-IP, immunofluorescence, neutralizing-antibody and dsRNA microinjection with spindle/MPF readouts in oocytes\",\n      \"pmids\": [\"19551325\", \"19439730\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the meiotic role is mechanistically distinct from apoptosis suppression unclear\", \"Single-lab oocyte system; direct partners of the spindle role undefined at this point\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified an evolutionarily acquired calcium-binding motif in the α5-α6 interhelical region, foreshadowing a Ca2+-related function.\",\n      \"evidence\": \"Site-directed mutagenesis, truncation constructs and phylogenetic analysis with biochemical readouts\",\n      \"pmids\": [\"21705382\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Ca2+ binding not demonstrated in cells\", \"Limited functional validation in the report\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the proteostatic control of BCL2L10 and expanded its function to autophagy suppression and a defined structural fold.\",\n      \"evidence\": \"Mass spectrometry, site-specific ubiquitin mutagenesis, linkage-specific antibodies, cycloheximide chase (K128 K48-ubiquitination; UBQLN1 stabilization); Co-IP/autophagy flux (Beclin-1); 1.9 Å crystal structure with Bim\",\n      \"pmids\": [\"22233804\", \"23563182\", \"22498477\", \"23235460\", \"22875003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E3 ligase for K128 ubiquitination not identified\", \"How ubiquilin stabilization and ubiquitin-driven degradation are coordinated unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established the ER/MAM Ca2+ axis, showing BCL2L10 inhibits the IP3 receptor and is antagonized by dephosphorylated IRBIT to license apoptosis, and linked it to meiotic spindle assembly via TPX2/Aurora A.\",\n      \"evidence\": \"Co-IP, MAM fractionation, Ca2+ imaging and phosphorylation assays (IRBIT); Co-IP, co-localization, RNAi and kinase activity assay (TPX2/Aurka)\",\n      \"pmids\": [\"27995898\", \"27753540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IRBIT phosphorylation state is sensed by BCL2L10 mechanistically unclear\", \"Aurora A regulation shown by RNAi correlation, not direct enzymatic mechanism\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed BH4-dependent IP3R inhibition at the ER as an anti-apoptotic mechanism with therapeutic relevance, as BH4 mimetic peptides suppress tumor growth.\",\n      \"evidence\": \"Confocal localization, Co-IP, BH4-deletion mutagenesis, Ca2+ release assays and in vitro/in vivo tumor models\",\n      \"pmids\": [\"29330143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IP3R inhibition and effector sequestration act independently in tumors unclear\", \"Specificity of BH4 mimetics for BCL2L10 over related proteins not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected BCL2L10 to mitophagy and autophagy regulation in tissue contexts, showing it inhibits phospho-Parkin and displaces PI3KC3 from Beclin-1.\",\n      \"evidence\": \"Co-IP with phospho-Parkin, siRNA/overexpression with mitophagy and apoptosis assays (HSCs); Co-IP, ELISA and autophagy flux (Beclin-1/PI3KC3 in hepatoma)\",\n      \"pmids\": [\"30635551\", \"30696802\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Parkin inhibition is via direct dephosphorylation or steric block unresolved\", \"Single-lab, tissue-specific findings; generality across cell types untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed BCL2L10 in cancer drug-resistance circuits, defining STAT3 transcriptional control, UBQLN4-mediated stabilization, and a BOK interaction driving persister-cell phenotypes.\",\n      \"evidence\": \"ChIP/reporter/mutagenesis and siRNA with drug-sensitivity readouts (STAT3, melanoma); Co-IP and genetic screening (UBQLN4); Co-IP and MOMP/EMT assays (BOK, lung cancer)\",\n      \"pmids\": [\"33396645\", \"34245648\", \"39996719\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect nature of BOK-driven sublethal MOMP unclear\", \"How STAT3, ubiquilin stabilization, and degradation jointly set BCL2L10 levels in tumors not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The E3 ubiquitin ligase that drives K48/K128 turnover, the structural mechanism of the Nur77-induced anti-to-pro-apoptotic switch, and how the apoptotic, Ca2+, autophagic, and meiotic roles are coordinated in vivo remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No identified E3 ligase for BCL2L10 degradation\", \"No structural model of the pro-apoptotic conformation\", \"No integrated in vivo model linking the multiple cellular functions\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [4, 14, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 18, 13]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [9, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [16, 18]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [24, 9, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 3, 4]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 20, 19]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [16, 18]}\n    ],\n    \"complexes\": [\"Bcl-B:Bim complex\", \"IRBIT-Bcl2l10 complex at MAMs\", \"TPX2-containing meiotic spindle complex\"],\n    \"partners\": [\"BAX\", \"BIM\", \"BECN1\", \"ITPR1\", \"IRBIT\", \"APAF1\", \"BOK\", \"UBQLN1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}